AlphAIAlphAI — Financial news for AI agents
investing.comOCT 22 min read$GKOS

Stifel reiterates Glaukos stock rating on strong Epioxa survey

Stifel maintained a Buy rating and $190 price target for Glaukos (NYSE:GKOS) after a survey showed strong demand for its Epioxa product, with Q3 2026 procedures increasing fourfold. The firm estimates Q3 Epioxa sales between $30M and $44M, and Q4 sales between $65M and $70M. Glaukos reported Q2 2026 revenue of $185.6M, up 49.5% YoY, exceeding expectations and prompting multiple analysts to raise price targets.

Original reporting
investing.com
Published Oct 2, 2026, 12:46 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 12:53 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$GKOS
Bullish
medium confidence
Mentioned
$GKOS
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$GKOSBullishHigh
01

Why it matters

The upgrade reinforces bullish sentiment and may trigger short covering.

02

Market read

Analyst upgrade with new price target provides a clear short‑term trading catalyst for GKOS.

03

What to watch

Potential reimbursement challenges and competition from emerging therapies are not addressed.

Relevance 6/10Novelty 7/10Timing: today

Background

Stifel's reiteration follows Glaukos' recent strong Q2 earnings and multiple analyst target raises.

Company-level read

Ticker impact

$GKOSBullishMedium confidence
Context

Stifel reiterated a Buy rating and raised the price target to $190 for Glaukos (GKOS) after a bullish Epioxa survey showing a fourfold increase in Q3 procedures.

Expected impact

likely upward pressure as the market prices in the higher target and strong survey data

Evidence & confidence

The new survey data and target raise are fresh information that could attract buying interest today.

Market effects

Sector

Positive outlook for ophthalmology devices may lift peers in the eye‑care sector.

Regional

U.S. biotech and medical device stocks could see modest gains.

Global

Limited to markets tracking U.S. healthcare equities.

Counterpoint

What could challenge this read

The survey may overstate demand; execution risk could temper price gains.

Key entities

  • company
    Glaukos Corporation

    U.S. ophthalmic device maker

  • analyst
    Stifel

    Equity research firm issuing the rating

Read at source← All news

Related articles

OCT 9
$GKOSMed

Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal

Glaukos Corporation (GKOS) licensed RO-104, a tri-specific biologic for retinal diseases, from RevOpsis Therapeutics. The deal grants GKOS exclusive rights to RevOpsis' RevMod platform for up to four additional candidates. GKOS stock fell 6.3% post-announcement but is up 42.8% year-to-date. The agreement aims to expand GKOS' retinal therapeutics pipeline and market presence.

theglobeandmail.com3 min
OCT 9
$GKOSMed

Glaukos Corp (GKOS) Reports Positive Phase 4 Trial Results for i

Glaukos Corp (GKOS) reported positive phase 4 trial results for its iDose TR implant, showing significant reduction in intraocular pressure. The company trades at a P/S ratio of 15.24, above historical and industry medians, reflecting growth expectations. It has a GF Score of 79, indicating strong growth and financial health despite unprofitability. Insiders sold $67.8M in shares over the past year, while institutional investors increased holdings.

gurufocus.com2 min
OCT 9
$GKOSMed

Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye Therapy - Glaukos (NYSE:GKOS)

Glaukos (NYSE:GKOS) reported positive Phase 4 trial results for its iDose TR therapy combined with cataract surgery. The treatment reduced intraocular pressure by 11.1 mmHg vs. 7.4 mmHg for surgery alone, meeting primary efficacy goals. The study showed no serious safety issues. The therapy aims to improve patient compliance with long-lasting drug delivery. GKOS shares are up 0.12% at $161.49.

benzinga.com2 min
OCT 9
$GKOSMedAI 9/10

Glaukos Reports Positive Phase 4 Results for iDose TR

Glaukos Corp. reported positive Phase 4 results for its iDose TR glaucoma treatment, meeting the primary endpoint and showing superiority in reducing intraocular pressure. The company also secured an exclusive licensing agreement with RevOpsis Therapeutics for retinal disease treatments. Shares of Glaukos (GKOS) were trading at $161.16 with a $9.5 billion market cap.

ocbj.com2 min